NCT00568750 is a Phase 2 clinical trial of dasatinib in Gastrointestinal Stromal Tumor, sponsored by Swiss Cancer Institute.

Who is sponsoring NCT00568750?

NCT00568750 is sponsored by Swiss Cancer Institute.

What drugs are being tested in NCT00568750?

Interventions in NCT00568750: dasatinib.

What condition does NCT00568750 study?

NCT00568750 studies Gastrointestinal Stromal Tumor.

Is NCT00568750 still recruiting?

NCT00568750 is currently completed. Last updated 17 June 2019.

Last reviewed 2019-06-17 · How we verify

NCT00568750

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Completed Phase 2 Last updated 17 June 2019

What this trial tests

Phase 2 trial testing dasatinib in Gastrointestinal Stromal Tumor in 47 participants. Completed in 16 May 2018.

Timeline

22 January 2008

Primary endpoint
18 January 2012

16 May 2018

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	47
Start date	22 January 2008
Primary completion	18 January 2012
Estimated completion	16 May 2018
Sites	18 locations across France, Finland, Switzerland, Germany

Drugs / interventions tested

dasatinib (dasatinib) — full drug profile →

Conditions studied

Gastrointestinal Stromal Tumor — all drugs for Gastrointestinal Stromal Tumor →

Sponsor

Swiss Cancer Institute

Who can join

Adults 18 to 120, any sex, with Gastrointestinal Stromal Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dasatinib works as first-line therapy in treating patients with gastrointestinal stromal tumors.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors.
Sun Y, Yue L, Xu P, Hu W. · · 2022 · cited 27× · PMID 36119525 · DOI 10.3389/fonc.2022.927587
Role of the ABL tyrosine kinases in the epithelial-mesenchymal transition and the metastatic cascade.
Luttman JH, Colemon A, Mayro B, Pendergast AM. · · 2021 · cited 26× · PMID 34022881 · DOI 10.1186/s12964-021-00739-6
Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma.
Salguero-Aranda C, Olmedo-Pelayo J, de Álava E, Amaral AT, et al · · 2022 · cited 8× · PMID 36551696 · DOI 10.3390/cancers14246211
Chromatin Dynamics in Digestive System Cancer: Commander and Regulator.
Li Z, Zhao B, Qin C, Wang Y, et al · · 2022 · cited 3× · PMID 35965507 · DOI 10.3389/fonc.2022.935877

Verify or expand the search:

Other trials of dasatinib

Trials testing the same drug.

NCT03844360 — Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease · Phase 4 · recruiting
NCT02326311 — Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response · Phase 3 · completed
NCT01990196 — Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer · Phase 2 · active not recruiting
NCT01876953 — Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia · Phase 1, PHASE2 · terminated
NCT01234935 — Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer P · Phase 2 · completed

Other recruiting trials for Gastrointestinal Stromal Tumor

Currently open trials in the same condition.

NCT04933669 — Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors · Phase 2 · recruiting
NCT02834013 — Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · Phase 2 · active not recruiting
NCT00265798 — Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Tr · Phase 2 · active not recruiting

Other Swiss Cancer Institute trials

Trials by the same sponsor.

NCT07158489 — Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC · Phase 2 · not yet recruiting
NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
NCT06452394 — NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline · Phase 2 · recruiting
NCT06114108 — Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients · NA · recruiting
NCT04629781 — Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00568750 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Swiss Cancer Institute
Last refreshed: 17 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00568750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing